NCT06972732 A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
| NCT ID | NCT06972732 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Condition | Type 2 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 204 participants |
| Start Date | 2025-06-11 |
| Primary Completion | 2026-10-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.
Eligibility Criteria
Inclusion Criteria: * Has voluntarily agreed to participate in this clinical trial. * Adults over 19 years of age * Diagnosed with type 2 diabetes Exclusion Criteria: * Has severe renal and liver disorders * Has type 1 diabetes * Those who are participating or have participated in other clinical trials and administered their investigational products within 8 weeks before the screening date for this study * Those who are deemed ineligible to participate in the study by the investigator
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.